1. Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial
   Stefan Kasper et al, 2020, Clinical Colorectal Cancer CrossRef
2. An Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer: A Narrative Review
   Giulia Fornasier et al, 2018, Advances in Therapy CrossRef
3. Real-world comparison between weekly versus biweekly dosing of cetuximab for metastatic colorectal cancer
   Himani Aggarwal et al, 2023, Journal of Comparative Effectiveness Research CrossRef
4. Cetuximab every 2 weeks versus standard weekly dosing administration schedule
   Carsten Bokemeyer et al, 2024, Future Oncology CrossRef
5. Optimizing the Dosing Regimen of Cetuximab and Ramucirumab Using the Model‐Informed Drug Development Paradigm
   Lan Ni et al, 2023, Clinical Pharmacology & Therapeutics CrossRef
6. Efficacy and Safety of Cetuximab Dosing (biweekly vs weekly) in Patients with KRAS Wild-type Metastatic Colorectal Cancer: A Meta-analysis
   Aparna R Parikh et al, 2022, The Oncologist CrossRef
7. Radiomics in Oncological PET/CT: Clinical Applications
   Jeong Won Lee et al, 2018, Nuclear Medicine and Molecular Imaging CrossRef
8. Effects of different administration strategies of cetuximab on remission rate, MMPs, miR-106b-5p, PCAT-1, and adverse reactions in patients with RAS wild-type CRC liver metastasis
   Chao Wang et al, 2022, World Chinese Journal of Digestology CrossRef
9. A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer
   Kathleen N. Moore et al, 2021, Targeted Oncology CrossRef